Capricor stock falls amid data for duchenne muscular dystrophy study

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


Capricor Therapeutics (NASDAQ:CAPR) reported 18-month results from its ongoing HOPE-2 open label extension (OLE) study in patients with later-stage Duchenne muscular dystrophy (DMD).

DMD is genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!